Pharming Group valuation
€1.08Change from previous close: −3.05%Absolute change: −€0.03
Valuation
The P/E ratio is 36.1. The average price target of 4 analysts is €2.24.
Data as of November 22, 2026
Pharming Group compared with similar companies
Pharming Group's P/E (trailing 12 months): 36.1, +145% against the median of a group of 7 similar companies (14.7).
| Metric | Pharming Group | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 36.1 | 14.7 | 4.92 – 28.1 | High |
| Forward P/E | 32.2 | 52.3 | 19.9 – 96.9 | Middle |
| EV/EBITDA | 11.7 | 13.3 | 12.4 – 15.8 | Low |
| Price/book | 2.85 | 4.45 | 2.62 – 5.35 | Middle |
| Price/sales | 1.98 | 4.20 | 3.13 – 22.7 | Low |
| Gross margin | 87.7% | 87.2% | 71.5% – 93.2% | Middle |
| Operating margin | 12.8% | 19.6% | -70.7% – 36.9% | Middle |
| Net margin | 6.3% | 10.5% | 0.0% – 43.9% | Middle |
| ROE | 8.7% | 16.3% | -5.5% – 27.7% | Middle |
| Debt/equity | 0.39 | 0.05 | 0.03 – 0.34 | High |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- €765.47M
- Enterprise value
- €664.71M
- EV/revenue
- 1.72
Profitability and growth
- ROA
- 6.4%
- ROIC
- 7.7%
- Revenue growth (year over year)
- 20.8%
- Earnings growth (year over year)
- 74.9%
Financial health
- Total cash
- €189.56M
- Total debt
- €114.51M
- Current ratio
- 3.23
- Quick ratio
- 2.65
- Altman Z-Score
- 3.90
- Piotroski F-Score
- 5.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- €2.24
- Median price target
- €2.27
- High price target
- €2.50
- Low price target
- €1.94
- Analysts with a price target
- 4
- Consensus
- Strong buy
- Forward EPS
- €0.03
- EPS estimate, current year
- €0.03
Shares and trading
- Beta
- 0.05
- Average volume
- 8.47M
- Shares outstanding
- 707.78M
- Float
- 673.18M
- Institutional ownership
- 22.2%
- Insider ownership
- 1.0%
